APPL1 Lentiviral Activation Particles (m): sc-428481-LAC

Appl1 encodes APPL1, an endosomal adaptor protein that links Rab5-positive early endosomes to signal transduction, integrating cues from receptor tyrosine kinases and adiponectin receptors. Through interactions with AKT and other signaling intermediates, APPL1 modulates PI3K–AKT signaling, insulin sensitivity, and glucose homeostasis, while also influencing endocytic trafficking and receptor recycling. In mouse cells, APPL1 has been used to study cross-talk between metabolic and growth-factor pathways, including regulation of AMPK- and MAPK-associated responses. Dysregulation of APPL1-dependent signaling is relevant to mechanistic research in metabolic dysfunction, vascular biology, and inflammation-associated phenotypes.

APPL1 Lentiviral Activation Particles (m) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient Appl1 upregulation across a broader range of human cell types.

APPL1 Lentiviral Activation Particles (m) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the Appl1 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous APPL1 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native Appl1 genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.